Intellia Therapeutics (NASDAQ:NTLA) Trading Up 10% – Still a Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price traded up 10% on Friday . The stock traded as high as $10.69 and last traded at $10.60. 1,050,652 shares changed hands during trading, a decline of 63% from the average session volume of 2,842,250 shares. The stock had previously closed at $9.64.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. William Blair reaffirmed a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. The Goldman Sachs Group dropped their price objective on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, January 14th. Chardan Capital boosted their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. Wells Fargo & Company dropped their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Wedbush reiterated a “neutral” rating and issued a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $48.71.

Intellia Therapeutics Trading Up 11.0 %

The company has a market cap of $1.09 billion, a price-to-earnings ratio of -1.97 and a beta of 1.80. The company’s 50 day moving average price is $11.25 and its 200 day moving average price is $16.41.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 over the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently modified their holdings of NTLA. Eastern Bank acquired a new stake in Intellia Therapeutics in the third quarter valued at $41,000. Values First Advisors Inc. purchased a new position in shares of Intellia Therapeutics in the 3rd quarter valued at about $54,000. Sterling Capital Management LLC lifted its stake in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics during the fourth quarter worth about $40,000. Finally, Resona Asset Management Co. Ltd. purchased a new stake in Intellia Therapeutics during the fourth quarter worth about $43,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.